<DOC>
	<DOCNO>NCT02784015</DOCNO>
	<brief_summary>To evaluate treatment outcome unresectable soft tissue sarcoma use response base treatment</brief_summary>
	<brief_title>Response Based Treatment Children With Unresectable Localized Soft Tissue Sarcoma</brief_title>
	<detailed_description>Response initial chemotherapy one important prognostic factor many cancer . In study , treatment tailor accord treatment response assess tumor volume reduction , necrosis rate residual fludeoxyglucose ( FDG ) uptake positron emission tomography ( PET ) scan .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Patients unresectable localized high grade soft tissue sarcoma Patients organ dysfunction ( ejection fraction , liver function test , creatinine &gt; CTCAE grade 2 )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>